27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Nutrition Facts labels help cut through confusing grocery-store marketing and make it easier to choose foods that fit your health goals and budget. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results of this study confirm that some sociodemographic groups are more likely to choose priorities that reflect contextual constraints in their lives than others. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The objective of a new report, ‘European Dementia Monitor 2017: comparing and benchmarking national dementia strategies and policies’, is to provide a benchmark of national dementia policies in order to compare the responses of European countries to the dementia challenge in different domains. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although extensively studied in the acute care setting, the syndrome of delirium— also referred to as acute confusion—has been a subject of relatively few studies in the long-term care (LTC) setting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Public health surveillance of overweight prevalence is essential to assess the extent of the problem, identify regions and groups most affected and inform policy-making. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results demonstrate similar poverty patterns as per county data findings on Kenya poverty report, 2022. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The World Health Organisation (WHO) predicts that, world-wide, depression will be the second largest source of burden of disease by 2020. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
If it takes a village to raise a child, it takes one to care for our ill as well. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Progressive myoclonic epilepsy (PME) is a syndrome characterized by myoclonias, epilepsy, progressive dementia and other neurological deficits. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This article details the determinant bundle of store choice and the role of price as one of the major components in initial and ongoing store selection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As Deputy Gibbs’ father says, “I know it’s hard to find people in this world,” he said. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
But advocacy groups, including APA, have been bracing for enormous complications with transitioning these beneficiaries— some 2 million of whom are believed to have mental illness—into the new program. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
And, she noted, data from the 2009-2011 Medical Expenditure Panel Survey have shown that “high-need adults spent more on health care but were less likely to report that the health system works for them.” 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results were announced earlier this month at a press conference in Washington D.C., and were published in the May American Journal of Psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Back to table of contents Previous article Next article Association NewsFull AccessAssembly Votes Challenge Threats to Patient CareKen HausmanKen HausmanSearch for more papers by this authorPublished Online:1 Dec 2006https://doi.org/10.1176/pn.41.23.0004Patient care issues had a prominent place on the agenda for the APA Assembly's November meeting in Washington, D.C., and several dealt with prescribing concerns in a health care environment that is not always patient friendly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There is explosive growth in the number of older Americans, who are at higher risk for cancer. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In January, the NHS presented its long-awaited plan to transform care over the next 10 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We know that lifestyle changes, such as to diet and exercise regimens, can have an impact on the risk of developing dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
But when I imagined the short, awkward conversations that would have been likely to ensue, conversations whose power to irk me would almost certainly be out of all proportion to their length, I always made the same swift choice: leave it. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On June 7, 2021, the FDA granted accelerated approval to aducanumab (Aduhelm), the first new Alzheimer's drug approved since 2003 and the first ever approved for a mechanism thought to modify disease course. 3 key findings →
Design: regulatory decision Evidence: preliminary
Full summary, score breakdown and related studies → Original source
The Phase 2a TOGETHER trial tested bepranemab, an antibody targeting the tau protein (rather than amyloid), in 466 people with prodromal-to-mild Alzheimer's disease over 80 weeks. 3 key findings →
Design: phase-2-trial Participants: 466 Evidence: early
Full summary, score breakdown and related studies → Original source
An independent US drug-pricing watchdog analyzed how lecanemab's actual price compares to its clinical benefit. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Researchers tested whether a tablet-based cognitive test (TabCAT) could substitute for traditional paper-and-pencil memory tests in people with early-onset Alzheimer's. Scores on the tablet's attention/executive tasks correlated strongly (above 0.7) with standard tests like the MMSE and MoCA, and one subtest could distinguish people with amyloid plaques from those without with good accuracy (AUC 0.82). 5 key findings →
Design: cross-sectional Participants: 475 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Eli Lilly's newer anti-amyloid antibody remternetug showed fast, dose-dependent removal of amyloid plaques in a small early trial: three-quarters of people getting the higher doses had their brain amyloid drop below the threshold used to call a scan 'positive' within about six months. 5 key findings →
Design: RCT Participants: 41 Evidence: early
Full summary, score breakdown and related studies → Original source
Trontinemab is designed with a molecular 'shuttle' that helps it cross into the brain more efficiently than older anti-amyloid antibodies, aiming for faster plaque removal at lower doses. 5 key findings →
Design: phase-2-trial Participants: 13 Evidence: early
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →